Hemogenyx Pharmaceuticals PLC HOPHF
$2.33
Last Updated: Apr 09, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
HOPHF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Hemogenyx Pharmaceuticals PLC is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Hemogenyx Pharmaceuticals PLC. Stock Analysis HOPHF
United States Health Care Micro Cap HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to address current problems associated with the treatment of blood disorders such as cancers and autoimmune diseases, with bone marrow, or hematopoietic stem cell, transplants, and with viral infections. The firm is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Hemogenyx Pharmaceuticals PLC (HOPHF) Chart
Financial Metrics & Statements of Hemogenyx Pharmaceuticals PLC (HOPHF)
FAQ's for Hemogenyx Pharmaceuticals PLC (HOPHF)
- As of August 2026, Hemogenyx Pharmaceuticals PLC HOPHF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hemogenyx Pharmaceuticals PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Hemogenyx Pharmaceuticals PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Hemogenyx Pharmaceuticals PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Hemogenyx Pharmaceuticals PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Hemogenyx Pharmaceuticals PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Hemogenyx Pharmaceuticals PLC (HOPHF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
